Cosmos Health Inc. (COSM)
COSM trades on Nasdaq in Health Care, Other Pharmaceuticals. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1474167/000147793226002278/0001477932-26-002278-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | COSM on Nasdaq |
| Sector | Health Care |
| Industry | Other Pharmaceuticals |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001474167 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $65.3M |
| Net income | -$19.1M |
| Operating income | -$16.7M |
| Net margin | -29.3% |
| Operating margin | -25.6% |
| Revenue growth | +19.9% |
| Cash | $716K |
| Total assets | $65.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the date of this filing." | 10-Q 2026-08-18 |
| Cash and burn | $1.8M cash; operating cash flow -$2.5M a quarter. | Report 2026-06-30 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-08-18 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2026-11-13 | Source 2026-11-13 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2025-12-18 |
| Auditor | RBSM LLP, NEW YORK, New York, United States | PCAOB Form AP 2026-04-16 |
| Late filings, 12 months | 3 NT notices | NT 10-Q 2026-08-14 |
| Insider trades, 12 months | Bought $1.7M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $19.0M | -$6.1M | -$1.7M | $1.8M | $3.2M | $73.7M | 10-Q 2026-08-18 |
| Q1 2026 2026-03-31 | $17.9M | -$2.8M | -$1.1M | $515K | $3.5M | $69.5M | 10-Q 2026-05-20 |
| Q4 2025 2025-12-31 | $19.7M | -$10.1M | -$4.6M | $716K | $3.8M | $65.3M | 10-K 2026-04-15 |
| Q3 2025 2025-09-30 | $17.1M | -$5.4M | -$2.5M | $889K | $5.4M | $59.8M | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $14.7M | -$2.8M | -$1.2M | $656K | $5.2M | $55.1M | 10-Q 2026-08-18 |
| Q1 2025 2025-03-31 | $13.7M | -$818K | -$186K | $743K | $4.9M | $53.6M | 10-Q 2026-05-20 |
| Q4 2024 2024-12-31 | $14.2M | -$3.3M | -$3.8M | $315K | $4.1M | $54.4M | 10-K 2026-04-15 |
| Q3 2024 2024-09-30 | $12.4M | -$8.4M | $740K | $3.3M | $4.3M | $56.0M | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -28.3% |
| 1 month | -40.6% |
| 3 months | +0.5% |
| Year to date | -58.2% |
| 1 year | -71.5% |
| From 52-week high | -71.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-12. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Other Pharmaceuticals
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NUS | Nu Skin Enterprises Inc. | $3.93 | -2.48% | $191.3M |
| ZSTK | ZeroStack Corp. | $2.80 | -1.75% | $61.1M |
| ESYN | EnerSyn Global Inc. | $1.25 | 0.00% | $37.2M |
| HLF | Herbalife Ltd. Common Shares | $16.15 | +1.19% | $1.7B |
| HKPD | Cellyan Biotechnology Co. Ltd | $1.61 | -0.62% | $4.0M |
| MEDS | DataMeds AI Inc. | $0.6421 | -13.68% | $3.1M |
| CAH | Cardinal Health Inc. | $283.85 | +0.98% | $65.6B |
| COR | Cencora Inc. | $356.94 | -0.58% | $68.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier